Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "certificate of analysis/1000"

Looking for quality documents?
event icon
XCell™ Lab System for Simplified and Scaled-down Intensification
XCell ATF® technology can expand bioprocess facility capacity and throughput with cell densities up 300 x 106 VCD/mL. The newly launched XCell™ Lab Controller System accelerates development of robust intensified processes at volumes as low as 0.5L, reducing media costs per run and facilitating advancement to manufacturing. The benefits of key features such as a 0.5L single-use device, permeate pressure recording, a pump-based control logic loop, support for two devices per controller and a modern smartphone-like software interface are be discussed.
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
external link icon
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “ Perspectives on Progress ”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance. Olivier Loeillot, President and Chief Executive Officer at Repligen, said, “At Repligen, we take a pragmatic approach
external link icon
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “ Advancing Impacts ”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD). Olivier Loeillot, President and Chief Executive Officer at Repligen said, “I am delighted with the progress we’ve made
external link icon
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making an Impact ”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “ Committed to Making a Difference ”. Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD). See the Sustainability section of Repligen’s website for more information.
Tony Hunt, Chief Executive Officer at Repligen said, “Our initial
external link icon
Repligen Receives Notice of Allowance for Recombinant Protein A Patent
event icon
Dynamic Dialysis: A Novel Method for Process Scale Membrane Separation
Learn how the SpectraFlo™ Dynamic Dialysis System accelerates membrane separation of fragile proteins, viscous fluids and polymer gels, such as hyaluronic acid. September 24, 2018 | 24 minutes
external link icon
Repligen Acquires Business of Novozymes Biopharma Sweden AB Creates World-Leading Supplier of Products for Manufacturing Biologic Drugs Accelerates Path to Near-Term, Sustainable Profitability
external link icon
Repligen Announces Conference Call to Discuss Phase 3 Clinical Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9th, 8:30 a.m. EST
external link icon
Repligen Hires Ralf Kuriyel as Senior Vice President of Research & Development
WALTHAM, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the appointment of Ralf Kuriyel to the position of Senior Vice President of Research & Development (R&D). Mr. Kuriyel was most recently Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (Pall), a global leader in the high-tech filtration, separation and purification markets, whose acquisition by Danaher Corporation was completed in August 2015. During his 11-year tenure at Pall, Mr. Kuriyel played a key role in expanding the Global Applications R&D function to include cell culture and single-use applications, process monitoring technologies, and process development services. Prior to Pall, Mr. Kuriyel held various technology and applications development management roles within the bioprocess and biopharm divisions of Millipore
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support